Literature DB >> 11489768

Differential impact on survival of electrocardiographic Q-wave versus enzymatic myocardial infarction after percutaneous intervention: a device-specific analysis of 7147 patients.

G W Stone1, R Mehran, G Dangas, A J Lansky, R Kornowski, M B Leon.   

Abstract

BACKGROUND: The relative prognostic importance of ECG myocardial infarction (MI) after intervention compared with varying degrees of enzymatic elevation has not been characterized, and the device-specific implications of periprocedural MI are also unknown. METHODS AND
RESULTS: Serial creatine phosphokinase (CPK)-MB levels were determined after elective percutaneous intervention of 12 098 lesions in 7147 consecutive patients at a tertiary referral center. Procedural, in-hospital, and follow-up data were collected by independent research nurses, and clinical and ECG events were adjudicated by a separate committee. Stents were implanted in 50.6% of lesions, atheroablation was performed in 54.8%, and PTCA alone was performed in 9.8%. The peak periprocedural CPK-MB level was >3x the upper limit of normal (ULN) in 17.9% of patients, and Q-wave MI developed in 0.6%. By multivariate analysis, the periprocedural development of new Q waves was the most powerful independent determinant of death (2-year mortality rate, 38.3%; hazard ratio, 9.9; P<0.0001). Non-Q-wave MI with CPK-MB >8x ULN was also a strong predictor of death (2-year mortality rate, 16.3%; hazard ratio, 2.2; P<0.0001); survival was unaffected by lesser degrees of CPK-MB elevation. Though CPK-MB elevation was more common after atheroablation and stenting than PTCA, the rates of Q-wave MI and survival were device-independent.
CONCLUSIONS: Myonecrosis after percutaneous intervention is common in a high-risk referral population dominated by atheroablation and stent use. Large periprocedural infarctions (signified by new Q waves and CPK-MB >8xULN) are powerful determinants of death, whereas lesser degrees of CPK-MB release and specific device use do not adversely affect survival.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11489768     DOI: 10.1161/hc3101.093902

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  19 in total

1.  Cost-effectiveness of paclitaxel-coated balloon angioplasty and paclitaxel-eluting stent implantation for treatment of coronary in-stent restenosis in patients with stable coronary artery disease.

Authors:  Klaus Bonaventura; Alexander W Leber; Christian Sohns; Mattias Roser; Leif-Hendrik Boldt; Franz X Kleber; Wilhelm Haverkamp; Marc Dorenkamp
Journal:  Clin Res Cardiol       Date:  2012-02-21       Impact factor: 5.460

2.  Frequency, risk factors, and effect on long-term survival of increased troponin I following uncomplicated elective percutaneous coronary intervention.

Authors:  Henry S Loeb; Jayson C Liu
Journal:  Clin Cardiol       Date:  2010-12       Impact factor: 2.882

3.  Does the use of rotational atherectomy procedure during percutaneous coronary interventions influence the frequency of procedure-related myocardial injury assessed by cardiac magnetic resonance?

Authors:  Rafał Januszek; Stanisław Bartuś
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

4.  Incidence of periprocedural myocardial infarction and cardiac biomarker testing after percutaneous coronary intervention in Japan: results from a multicenter registry.

Authors:  Takahide Arai; Shinsuke Yuasa; Hiroaki Miyata; Akio Kawamura; Yuichiro Maekawa; Shiro Ishikawa; Shigetaka Noma; Soushin Inoue; Yuji Sato; Shun Kohsaka; Keiichi Fukuda
Journal:  Heart Vessels       Date:  2012-12-29       Impact factor: 2.037

5.  Timing of Loading Dose of Atorvastatin in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes: Insights From the SECURE-PCI Randomized Clinical Trial.

Authors:  Renato D Lopes; Pedro G M de Barros E Silva; Isabella de Andrade Jesuíno; Eliana Vieira Santucci; Lilian Mazza Barbosa; Lucas Petri Damiani; Renato Hideo Nakagawa Santos; Ligia Nasi Laranjeira; Frederico Toledo Campo Dall Orto; Pedro Beraldo de Andrade; Igor Ribeiro de Castro Bienert; John H Alexander; Christopher B Granger; Otavio Berwanger
Journal:  JAMA Cardiol       Date:  2018-11-01       Impact factor: 14.676

6.  Changing nature of cardiac interventions in older adults.

Authors:  John A Dodson; Mathew S Maurer
Journal:  Aging health       Date:  2011-04

7.  Effects of Qishen Yiqi Dripping Pills () in Reducing Myocardial Injury and Preserving Microvascular Function in Patients Undergoing Elective Percutaneous Coronary Intervention: A Pilot Randomized Study.

Authors:  Gui-Xin He; Jun Xie; Hao Jiang; Wei Tan; Biao Xu
Journal:  Chin J Integr Med       Date:  2017-05-03       Impact factor: 1.978

Review 8.  Myocardial ischemia is a key factor in the management of stable coronary artery disease.

Authors:  Kohichiro Iwasaki
Journal:  World J Cardiol       Date:  2014-04-26

9.  Detection of coronary microembolisation by Doppler ultrasound during percutaneous coronary interventions.

Authors:  P Bahrmann; H R Figulla; M Wagner; M Ferrari; A Voss; G S Werner
Journal:  Heart       Date:  2005-09       Impact factor: 5.994

10.  A value-based analysis of hemodynamic support strategies for high-risk heart failure patients undergoing a percutaneous coronary intervention.

Authors:  David Gregory; Dennis J Scotti; Gregory de Lissovoy; Igor Palacios; Simon Dixon; Brijeshwar Maini; William O'Neill
Journal:  Am Health Drug Benefits       Date:  2013-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.